Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Composition : Olmesartan medoxomil 20 mg + chlorthalidone 12.5 mg tablet
Dosage Form : Tablet
Packaging Type : Alu Alu
Packaging : 10*10
Price : ₹1/-
This combination tablet brings together Olmesartan Medoxomil, a selective angiotensin II receptor blocker (ARB), and Chlorthalidone, a thiazide-like diuretic, for effective control of high blood pressure. Olmesartan lowers blood pressure by blocking angiotensin II at AT1 receptors, preventing vasoconstriction and promoting vascular relaxation. Chlorthalidone enhances the antihypertensive effect by promoting sodium and water excretion from the kidneys, reducing plasma volume and vascular resistance. Compared to Hydrochlorothiazide, Chlorthalidone provides a longer duration of action, making it suitable for 24-hour blood pressure control. The fixed-dose combination of 20 mg Olmesartan with 12.5 mg Chlorthalidone is often prescribed to patients whose hypertension is not adequately managed with monotherapy or who require a potent combination to achieve target blood pressure levels. This dual-acting therapy significantly reduces the risk of long-term cardiovascular complications such as heart attack, stroke, and chronic kidney disease.
Common side effects include dizziness, headache, fatigue, and mild gastrointestinal discomfort. Chlorthalidone may cause increased urination, electrolyte imbalances (low potassium, sodium, or magnesium), mild dehydration, and increased uric acid levels. Olmesartan can occasionally cause hypotension, particularly in volume-depleted patients. Rare side effects include kidney function changes, allergic reactions, or photosensitivity. Regular monitoring of blood pressure, kidney function, and serum electrolytes is recommended during treatment.
Olmesartan Medoxomil 20 mg + Chlorthalidone 12.5 mg Tablet is indicated for the management of essential hypertension in adults, especially in patients requiring combination therapy to achieve optimal blood pressure targets or those unresponsive to a single-agent treatment.
This medication should be used under medical supervision only. It is contraindicated in pregnancy, particularly during the second and third trimesters, due to the risk of fetal injury or death. Caution is advised in patients with kidney or liver impairment, severe dehydration, or electrolyte disturbances. Avoid combining with potassium supplements or potassium-sparing diuretics unless prescribed. Alcohol intake should be minimized, as it can enhance the blood pressure-lowering effect. The medicine is not recommended during breastfeeding. Do not discontinue the therapy abruptly without consulting a healthcare provider. Regular follow-up visits and lab monitoring are essential to ensure safety and effectiveness.
Store the tablets in a cool, dry place below 30°C. Protect from moisture, heat, and direct sunlight. Keep out of the reach of children and pets. Do not use the medication after the expiry date.
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg tablet
Composition : Olmesartan Medoxomil (20mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg) Tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan Medoxomil 40 mg tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg tablet